Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CRISPR Therapeutics AG - Common Shares
(NQ:
CRSP
)
56.40
-1.59 (-2.74%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CRISPR Therapeutics AG - Common Shares
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
34
35
Next >
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
↗
February 01, 2023
Via
Benzinga
Jim Cramer Says This Is 'One Of Those Crazy Science Stocks That In This Market Will Work Perfectly'
↗
February 01, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he really likes Qualtrics International Inc (NASDAQ: XM) as a
Via
Benzinga
3 Things About CRISPR Therapeutics That Smart Investors Know
↗
January 31, 2023
The gene-therapy specialist's near-term outlook is quite bullish.
Via
The Motley Fool
7 CRISPR Stocks With the Best Long-Term Potential
↗
January 30, 2023
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.
Via
InvestorPlace
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
↗
January 27, 2023
These companies have the therapies to boost revenue for a decade.
Via
The Motley Fool
5 Reasons to Buy Vertex Pharmaceuticals Now
↗
January 18, 2023
Vertex shares are extending last year's gains, and that trend probably isn't over.
Via
The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
↗
January 14, 2023
Vertex is heading for a new phase of growth.
Via
The Motley Fool
Expert Ratings for CRISPR Therapeutics
↗
January 05, 2023
Via
Benzinga
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later
↗
January 25, 2023
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.
Via
InvestorPlace
3 Gene Editing Stocks With the Best Long-Term Potential
↗
January 25, 2023
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space
Via
InvestorPlace
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
↗
January 22, 2023
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.
Via
The Motley Fool
3 Smart Stocks to Buy if a Recession Is on the Way
↗
January 21, 2023
Their products will enjoy strong demand regardless of what happens with the economy.
Via
The Motley Fool
CRISPR Therapeutics Stock: Bull vs. Bear
↗
January 19, 2023
Should investors buy this risky biotech stock as the company moves toward bringing its first major treatment to market?
Via
The Motley Fool
7 Biotech Stocks That Will Make You Rich in 10 Years
↗
January 18, 2023
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.
Via
InvestorPlace
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
↗
January 18, 2023
CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in 10 years.
Via
InvestorPlace
2 Stocks Down More Than 25% to Buy Right Now
↗
January 16, 2023
These companies are set for a new era of growth.
Via
The Motley Fool
5 Potentially Explosive Stocks to Buy in 2023
↗
January 13, 2023
These stocks all dropped in the double digits last year. But their future prospects are brilliant.
Via
The Motley Fool
More Likely to 5X First: CRISPR Therapeutics vs. InMode
↗
January 12, 2023
These two companies are in very different situations but could generate significant returns for investors.
Via
The Motley Fool
2 Growth Stocks You May Regret not Buying Right Now
↗
January 11, 2023
At their beaten-down valuations, these stocks have the potential to deliver some impressive returns.
Via
The Motley Fool
Can Cathie Wood Bounce Back in 2023?
↗
January 11, 2023
Wood sticks by her strategy, no matter what the general market does.
Via
The Motley Fool
2 Supercharged Stocks to Buy Right Now That Could Soar in 2023
↗
January 11, 2023
These stocks have been solid performers despite the macroeconomic uncertainties in 2022.
Via
The Motley Fool
2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years
↗
January 07, 2023
Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow.
Via
The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2023
↗
January 06, 2023
These biotechnology stocks are pushing ahead with promising innovations.
Via
The Motley Fool
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
↗
January 06, 2023
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.
Via
Investor's Business Daily
Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away'
↗
January 04, 2023
Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
↗
January 05, 2023
Via
Benzinga
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Rich Over Time
↗
January 04, 2023
Wood is bargain hunting now. And these buys may pay off big in the long run.
Via
The Motley Fool
3 Growth Stocks That Could Skyrocket 50% or More In 2023, According to Wall Street
↗
December 31, 2022
These stocks fell significantly in 2022. But analysts expect that huge rebounds could be on the way in the new year.
Via
The Motley Fool
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)
↗
December 30, 2022
Both stocks have fallen brutally this year, but only one has a chance to recover soon.
Via
The Motley Fool
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond
↗
December 29, 2022
These two biotechs are flying high right now.
Via
The Motley Fool
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
34
35
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
